Improved transfusion independence rates for momelotinib vs ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status

Among patients with myelofibrosis, achieving transfusion independence after receiving 24 weeks of therapy with JAK1/2 and ACVR1/ALK2 inhibitor momelotinib is associated with clinical benefit, according to analysis of the phase III SIMPLIFY 1 trial, which was presented during the 2021 European Hematology Association 2021 Virtual Congress. The benefit is irrespective of the degree of anemia, platelet count, or transfusion status at baseline among patients.